Curasight (CURAS) | Spotlight

Curasight is active in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio includes, for example, research and development within Positron Emission Tomography (PET) and related ancillary services. The business is operating with the largest presence within Scandinavia. Curasight is headquartered in Copenhagen.

Quotes for Curasight A/S

Right Now

+/-: -0.06
%: −2,35%
Latest: 2.49
High: 2.57
Low: 2.2
Volume: 25 084
Turnover (DKK): 60 874
Market Value (MDKK): 52,7
Time (Latest trade)

Board

CEO

Ulrich Krasilnikoff

Chairperson of the Board

Kirsten Drejer

Board

Andreas Kjær
Charlotte Vedel
Lars Trolle
Ulrich Krasilnikoff

News

2025-05-15 16:09:23 Subscription of new shares in the Right Issue 2025 exercised by Curasight management
2025-05-13 17:14:00 Notice of Annual General Meeting 2025
2025-05-13 08:46:30 Last day of the subscription period in Curasight’s rights issue of shares
2025-05-07 08:06:12 Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer
2025-05-02 07:30:53 THE SUBSCRIPTION PERIOD IN CURASIGHT’S RIGHTS ISSUE OF SHARES BEGINS TODAY

News agencies

2025-05-07 08:29:32 Finwire: Curasight väljer CRO för fas 1-studie med uTREAT i hjärncancer
2025-04-30 06:21:00 Finwire: Curasight handlas i dag på Spotlight exklusive teckningsrätt i företrädesemission
2025-04-25 08:34:34 Finwire: Curasight rapporterar minskad rörelseförlust
2025-04-24 08:52:53 Finwire: Curasight beslutar om villkor i aviserad företrädesemission
2025-04-07 07:10:54 Finwire: Curasight aviserar nyemission på cirka 100 miljoner danska kronor

Analysis

2025-04-29 Redeye: Curasight Q1: Securing runway to readouts - Redeye
2025-04-07 SEB Research: Curasight: Rights issue brings new investors, including partner Curium - SEB
2025-04-07 Redeye: Curasight: DKK100m rights issue announced - Redeye
2025-03-10 SEB Research: Curasight: Enticing short-term inflections, if funds secured - SEB
2024-12-11 Redeye: Curasight: TO2 program yielded DKK5.4m - Redeye

Videos

Largest Owners

Name	Capital %	Votes %	Date
Andreas Kjær	30,24	30,24	2023-12-31
UK Curacap ApS	19,46	19,46	2024-06-14
Carsten Haagen Nielsen	12,11	12,11	2023-12-31
Jacob Madsen	4,57	4,57	2023-12-31
Lars Trolle	2,95	2,95	2023-12-31
Chr. Olesen Holding A/S	2,01	2,01	2024-06-14
Gerhard Dal	0,33	0,33	2024-06-14
Per Falholt	0,33	0,33	2023-12-31
Johan Stein	0,20	0,20	2024-06-14
Charlotte Vedel	0,20	0,20	2023-12-31

Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Quotes for Curasight A/S

Right Now

Board

News

News agencies

Analysis

Videos

Curasight - Providing answers for cancer patients

Largest Owners

Insider trading

Key Numbers

Upcoming reports

Annual reports, prospectus etc.